External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology EHA 2024
Roche and Genentech at

EHA 2024

June 13 - June 16
Madrid, Spain / Virtual (Hybrid)
eha.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:15 AM
Duration 1hr Madrid, Spain
Diffuse large B-cell lymphoma: exploring opportunities for cure
Salles G, von Tresckow B, Fox C, Karimi Y
Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 1hr Madrid, Spain
Advancing terminal complement inhibition treatment in paroxysmal nocturnal hemoglobinuria (PNH): tackling patient challenges head on
Munir T, Vallejo C
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:00 AM
Duration 1hr Madrid, Spain
Glofitamab▼ monotherapy retreatment in patients with heavily pre-treated relapsed or refractory Non-Hodgkin lymphoma (NHL): results from a phase I/II study
Bachy E
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:00 PM
Duration 1hr Madrid, Spain
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2, and 3 and COMPOSER trials of patients with paroxysmal nocturnal hemoglobinuria (PNH)
Fu R
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Madrid, Spain
Phase III COMMODORE 1 and COMMODORE 2 trials: treatment satisfaction and preference in patients with paroxysmal nocturnal hemoglobinuria (PHN) treated with crovalimab and eculizumab or ravulizumab
Kulasekararaj A
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Madrid, Spain
Response in molecular subgroups and circulating tumor (CT)DNA kinetics in patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) treated with glofitamab▼ monotherapy
Carlo-Stella C
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Madrid, Spain
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the Phase III Pola▼-R-CHP vs R-CHOP (POLARIX) study
Salles G
Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Madrid, Spain
Treatment effectiveness of venetoclax in combination with hypomethylating agents in patient subgroups with acute myeloid leukemia: experience from routine clinical practices in the United States
Bachiashvili K
Haematology - Oncology | Leukemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:45 PM
Duration 90mins Hall Picasso
Glofitamab▼ plus gemcitabine and oxaliplatin (GLOFIT-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)
Abramson J
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:30 PM
Duration 75mins Hall Dali 2
Glofitamab▼ monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: updated analysis from a phase I/II study
Phillips T
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 75mins Hall Dali 2
Mosunetuzumab▼ demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study
Assouline S
Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:00 PM
Duration 1hr Madrid, Spain
The evolving role of T-cell engaging bispecific antibodies in relapsed/refractory follicular lymphoma
Ladetto M, Budde E, Dietrich S
Haematology - Oncology | Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:30 AM
Duration 75mins Hall Picasso
Cevostomab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: initial results from the Phase I/II CAMMA 2 study
Kumar S
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.